



## Press Release |

### FIRST QUARTER 2008 INTERIM STATEMENT

Louvain-la-Neuve, Belgium, May 13, 2008 – Embargo until 5:40 P.M. (Belgian time)  
IBA (Ion Beam Applications S.A.: Reuters IBAB.BR and Bloomberg IBAB.BB)

#### KEY FACTS AND FIGURES

### DOUBLE-DIGIT GROWTH IN SALES

For the first quarter of 2008, IBA recorded sales growth of 33.5 percent at actual exchange rates and 40.1 percent after adjustment for exchange rate effects.

#### RADIOISOTOPE PRODUCTION AND DISTRIBUTION

- Revenue growth of 9 percent for the quarter at constant exchange rates. Good volume growth in both Europe and the U.S., tempered by the fluctuation of the dollar.
- Opening of a new PET (Positron Emission Tomography) radiopharmaceutical plant in Guildford, Surrey, U.K. This new plant is the latest addition to the IBA distribution network, which encompasses 36 PET radiopharmaceutical production facilities worldwide.
- Implementation of a restructuring plan for CIS Bio (19.9 percent holding) to restore the profitability of money-losing operations.


#### TECHNOLOGY AND EQUIPMENT

- Sales revenues up 60.3 percent:
  - Sales revenue growth of 119.3 percent in Proton Therapy due to progress on contracts signed in 2006 and 2007.
  - Six PET cyclotrons sold in the first quarter of 2008, compared to three for the same period in 2007.
  - Dosimetry sales growth of 35.4 percent during the first three months of 2008, due in part to the first four orders for the new COMPASS® dosimetry solution, as well as to success in Asia.
  - In the field of electron beam accelerators (Rhodotron® and Dynamitron® industrial e-beam and X-ray accelerators), the quarter was marked by the sale of a Rhodotron® to PetroBeam, Inc., a U.S. technology development company in the oil services industry in which IBA has taken a 10-percent stake, together with warrants allowing it to raise its holding to around 20 percent at a future stage. During this quarter, IBA also sold the LEONI group an X-ray sterilization facility based on the Rhodotron® TT-1000 system. When this facility comes on line in 2009, it will be the first of its kind in operation.


## Press Release |

### SALES REVENUE BY BUSINESS SEGMENT

**First Quarter 2008**  
EUR 59.9 million



**First Quarter 2007**  
EUR 44.9 million



### OUTLOOK

At the close of the first quarter, IBA remains confident that it can increase recurring profit above the 2007 level while continuing its policy of investment in R&D and in sales and marketing.

### SHAREHOLDERS' CALENDAR

2008 General Shareholders' Meeting  
Announcement of results at June 30, 2008  
Announcement of results at December 31, 2008

May 14, 2008, 10:00 A.M.  
August 29, 2008  
March 5, 2009

### ABOUT IBA

IBA is a developer of precision solutions for cancer diagnosis and treatment. It also offers sterilization and ionization solutions for optimal everyday hygiene and safety. IBA is listed on the Euronext pan-European stock exchange and is included in the BelMid index.

Website: [www.iba-worldwide.com](http://www.iba-worldwide.com)

### Contact

#### IBA

Paul-Emmanuel Goethals  
Director, Corporate Business Development  
& Investor Relations  
Tel.: +32 10 47 58 16  
[paul-emmanuel.goethals@iba-group.com](mailto:paul-emmanuel.goethals@iba-group.com)